Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc. (formerly Nasdaq: THTX) generates news primarily as a commercial-stage specialty biopharmaceutical company focused on HIV-related therapies and corporate transactions. Company press releases and regulatory reports highlight developments in its product portfolio, scientific presentations, financial performance, and significant corporate events, including its acquisition by an affiliate of Future Pak.
News coverage for Theratechnologies includes updates on tesamorelin for injection and its commercial formulations. In 2025, the company announced the availability of EGRIFTA WR (tesamorelin) for injection in the United States for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy, following FDA approval earlier that year. Releases also describe the planned transition from EGRIFTA SV to EGRIFTA WR and provide information on patient support initiatives related to this change.
Another key stream of news involves scientific and clinical data. Theratechnologies has reported poster presentations at the American Conference for the Treatment of HIV (ACTHIV), including analyses from the VAMOS study on excess visceral abdominal fat and muscle quality in people with HIV, and a case series examining combined use of tesamorelin and GLP-1 receptor agonists. These items give readers insight into how the company positions its therapies within evolving HIV care.
Theratechnologies’ news flow has also featured financial reporting and strategic transactions. Quarterly results press releases summarize revenue from products such as EGRIFTA SV and Trogarzo, cost of goods sold, research and development spending, and adjusted EBITDA, with references to detailed MD&A and interim financial statements. In 2025, the company announced a definitive arrangement agreement with CB Biotechnology, an affiliate of Future Pak, followed by shareholder approval, court approval, and completion of the acquisition. Subsequent communications describe the expected delisting of its shares from the Toronto Stock Exchange and Nasdaq and its transition to a privately held company.
Investors and observers using this news page can review historical announcements on product availability, clinical data, financial performance, and the completed acquisition. This provides context on how Theratechnologies evolved from a dual-listed biopharmaceutical issuer into a privately held company affiliated with Future Pak.
Theratechnologies (NASDAQ: THTX) has completed its previously announced acquisition by Future Pak's affiliate CB Biotechnology. Under the arrangement, shareholders will receive US$3.01 per share in cash plus one contingent value right (CVR) worth up to US$1.19 in additional payments if certain milestones are achieved.
The fair market value of each CVR has been determined to be US$0.80 as of September 24, 2025. Following the acquisition, Theratechnologies shares will be delisted from both the Toronto Stock Exchange and Nasdaq Capital Market, and the company will cease to be a reporting issuer in Canada while deregistering shares under U.S. securities laws.
Theratechnologies (NASDAQ: THTX), a commercial-stage biopharmaceutical company, has received final approval from the Superior Court of Québec for its previously announced acquisition by Future Pak through its affiliate CB Biotechnology, LLC.
The arrangement was already approved by shareholders at a special meeting on September 12, 2025. Subject to remaining closing conditions, the acquisition is expected to complete around September 25, 2025.
Theratechnologies (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced that shareholders have overwhelmingly approved the previously announced plan of arrangement to be acquired by Future Pak affiliate CB Biotechnology, LLC.
The arrangement resolution received strong support with 97.44% approval from shareholders present or represented by proxy, and 97.43% approval from minority shareholders. The transaction's completion remains subject to customary closing conditions, including final approval from the Superior Court of Québec, with a hearing scheduled for September 16, 2025.
Theratechnologies (NASDAQ: THTX) has announced the commercial availability of EGRIFTA WR™, a new formulation of tesamorelin for injection, following FDA approval earlier this year. The drug is specifically indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy.
The improved formulation offers significant advantages over EGRIFTA SV®, including weekly reconstitution instead of daily and less than half the injection volume. EGRIFTA WR™ is supplied as four single-patient-use vials, each containing 11.6 mg of tesamorelin for seven daily 1.28 mg injections, and can be stored at room temperature. The formulation is patent protected until 2033.
The company is facilitating patient transition through its Thera Patient Support® program, offering free training by dedicated Nurse Navigators. EGRIFTA SV® will remain available during a transitional period as managed care plans expand coverage for EGRIFTA WR™.
Theratechnologies (NASDAQ: THTX) announced its upcoming special meeting regarding the acquisition by CB Biotechnology, an affiliate of Future Pak. The deal values THTX at US$3.01 per share in cash, plus contingent value rights (CVR) of up to US$1.19 per share tied to company milestones.
The total consideration represents a 216% premium to THTX's closing price on April 10, 2025. The Board unanimously recommends shareholders vote FOR the arrangement at the September 12, 2025 meeting. The transaction requires approval from 66⅔% of shareholders and a majority of minority shareholders. Support agreements have been secured from directors and officers holding 1.14% of shares, while Soleus Capital (10.4% holder) has indicated intention to support.
Theratechnologies (NASDAQ: THTX) reported Q2 2025 financial results with total revenue of $17.7 million, marking a 19.5% year-over-year decrease. For the first six months of 2025, revenue reached $36.8 million, down 3.9% from 2024. The company achieved positive Adjusted EBITDA for the fifth consecutive quarter, reaching $906,000 in Q2 2025.
EGRIFTA SV® sales declined 31.3% to $11.1 million in Q2, primarily due to supply disruption and higher government chargebacks. Trogarzo® net sales increased 13.4% to $6.6 million. The company reported a net loss of $4.5 million for Q2 2025, compared to a net profit of $987,000 in Q2 2024.
Subsequent to the quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak, leading to the withdrawal of its Fiscal 2025 guidance.
Theratechnologies (NASDAQ: THTX), a commercial-stage biopharmaceutical company, will release its second quarter 2025 financial results on Wednesday, July 9, 2025. The results will cover the period ended May 31, 2025. Due to a recently announced acquisition of the Company on July 2, 2025, management will not host a conference call to discuss the results.
Theratechnologies (NASDAQ: THTX) has entered into a definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak, in a deal valued at up to US$254 million. Shareholders will receive US$3.01 in cash per share plus one contingent value right (CVR) worth up to US$1.19 in additional payments tied to specific milestones.
The transaction represents a substantial premium of 126% (cash only) and 216% (including CVR) to THTX's Nasdaq closing price on April 10, 2025. The deal includes milestone payments linked to EGRIFTA franchise performance and combined EGRIFTA-Trogarzo franchise profits over a 36-month period post-closing.
The transaction, expected to close in Q4 2025, requires 66⅔% shareholder approval and court approval. Upon completion, Theratechnologies will become private and delist from both Nasdaq and TSX.
Theratechnologies (NASDAQ: THTX) held its annual virtual shareholders meeting on May 29, 2025. During the meeting, shareholders elected eight directors to the Company's Board for a one-year term. All proposed candidates were successfully elected with approval rates ranging from 77.98% to 84.03%. Joseph Arena received the highest shareholder support with 84.03% votes in favor, while Dawn Svoronos received 77.98% of favorable votes.
Additionally, shareholders appointed KPMG LLP as the Company's auditors for the current fiscal year and approved an omnibus long-term incentive plan benefiting directors, executive officers, and employees of the Company and its subsidiaries.
FAQ
What is the current stock price of Theratechnologies (THTX)?
What is the market cap of Theratechnologies (THTX)?
